SSY GROUP(02005.HK): Bumetanide API Approved by NMPA
NewTimeSpace: SSY Group Limited(02005.HK) announced that its Bumetanide has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Bumetanide is a loop diuretic, mainly indicated for the treatment of edema associated with heart failure, renal dysfunction and hepatic dysfunction.
NewTimeSpace: SSY Group Limited (02005.HK) issued a voluntary announcement on March 16, stating that its Bumetanide has been approved by the NMPA for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.
Bumetanide is a loop diuretic. It is mainly used for the treatment of edema associated with heart failure, renal and hepatic dysfunction.
It is also applied in the prevention of acute renal failure, and the treatment of hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, as well as acute drug and toxic poisoning.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY Group(02005.HK): Trustee Purchases 380,000 Shares on Open Market Under Restricted Share Award Scheme at Average Price of HK$2.2124
- SSY Group Signs Letter of Intent with Longhai Pharma for Four Biosimilars Including Ustekinumab and Dupilumab
- SSY Group (02005.HK) Secures Production Approval for Four Drugs; Second Domestic Firm to Launch Emedastine Difumarate Eye Drops
- SSY Group (02005.HK): Obtains Production Registration Approvals for Three Products; Fat-Soluble Vitamin Injection Approved as First Domestic Enterprise
- SSY Group (02005.HK): Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection Obtain Drug Production Registration Approvals
